Nominee director services: what they are, when they're legitimate, and when they create problems

Last updated: April 2026

Nominee director services: what they are, when they're legitimate, and when they create problems

If you've ever looked into offshore company formation, you've almost certainly encountered nominee director services—usually offered as an add-on alongside registered office addresses and company secretarial support. The pitch is typically some combination of privacy, local presence, and professional credibility.

Some of that pitch still holds in narrow circumstances. Most of it doesn't.

Nominee directors exist in a genuinely changed regulatory environment compared to ten years ago. UBO registers, automatic tax information exchange, and OECD anti-avoidance rules have collectively dismantled the privacy rationale that drove most nominee demand historically. What remains is a narrower set of legitimate use cases—mainly meeting statutory residency requirements—surrounded by a larger set of structures where nominees add cost and compliance risk without meaningful benefit.

This article explains what nominee directors actually are, where they remain legally useful, where they create problems with tax authorities, and how to assess whether your situation is one of the narrow cases where they make sense.

Note: This article covers the general regulatory framework as of April 2026. Rules on beneficial ownership disclosure, tax residency, and director requirements vary by jurisdiction and change frequently. Verify current requirements with a qualified corporate and tax advisor before making structural decisions.

Who this guide is NOT for

Before going further, it's worth being direct about who should stop reading here:

• You are a small founder considering a nominee director primarily for privacy reasons — the privacy benefit is largely gone in 2026, as explained below; this guide will likely save you €1,000–€2,000 a year
• You are looking for a way to make your company appear to be managed in a low-tax jurisdiction when it's actually managed from wherever you live — nominee directors do not fix this problem and often make it worse
• You have a purely domestic company structure with no cross-border element — nominee directors are irrelevant to your situation
• You have already confirmed with a specialist that your jurisdiction requires a resident director and you're looking for implementation details — this guide is more analytical than operational; a corporate service provider in your target jurisdiction will be more useful

If you're genuinely exploring whether a nominee director solves a real problem for your structure, read on.

What a nominee director actually is

A nominee director is a person who appears as a director in public company records but acts entirely on behalf of someone else—the beneficial owner, typically referred to as the UBO (Ultimate Beneficial Owner). The nominee holds the formal title; the UBO holds the actual authority and economic interest.

In practice, the nominee arrangement is documented through a private agreement. The nominee signs a resignation letter (undated, held by the UBO) and grants a general power of attorney. This allows the beneficial owner to act on behalf of the company while the nominee's name appears in public filings.

The nominee director typically:

• Signs documents on instruction from the UBO
• Appears in incorporation documents and company registers
• Has no independent authority over business strategy, finances, or operations
• Charges an annual fee for the service

What the nominee is not: a substitute for substance. A nominee does not change where a company is genuinely managed, does not create economic activity in a jurisdiction, and does not alter the tax analysis of where a company's profits can legitimately be sheltered.

Why nominee directors became popular — and why the original rationale has eroded

Nominee directors grew in popularity during a period when offshore structures could realistically offer three things: privacy from public records, the appearance of local substance for tax purposes, and access to treaty networks the UBO's home country didn't provide. All three rationales have been substantially weakened by regulatory changes over the past decade.

Privacy

Before beneficial ownership registers became widespread, nominee directors provided a genuine privacy shield. Public company records showed the nominee; the beneficial owner's name appeared nowhere in public filings.

That shield is largely gone. The EU's Anti-Money Laundering Directives have required member states to establish beneficial ownership registers since the Fourth AMLD (2017), with requirements progressively tightening. The UK introduced its People with Significant Control (PSC) register through the Companies Act 2006 as amended — since 2016, any person owning or controlling more than 25% of a UK company must be identified on a public register.

As of 2026, mandatory identity verification for UK directors and PSCs took effect under the Economic Crime and Corporate Transparency Act 2023. The UBO is now required to identify themselves to Companies House, regardless of whether a nominee director is in place.

Offshore jurisdictions that historically offered complete privacy have also moved. Most British Overseas Territories and Crown Dependencies — Cayman Islands, British Virgin Islands, Bermuda, Jersey, Guernsey — now maintain private registers of beneficial ownership accessible to tax and law enforcement authorities. The OECD's Common Reporting Standard (CRS), which 100+ jurisdictions have signed, requires financial institutions to report account holders and beneficial owners to their domestic tax authorities, who then share the data automatically with counterpart authorities in the account holder's home country.

CRS 2.0, effective January 2026, expanded reporting requirements further with additional data fields under the EU's DAC8 directive. A nominee director arrangement does not remove the UBO's obligation to be reported under CRS—it simply adds a layer that banks and regulators now treat as a compliance risk signal.

The practical result: your name as the beneficial owner is known to your home country's tax authority whether or not a nominee director is in place. The privacy benefit of nominee directors has been substantially eliminated for tax and regulatory purposes. It may still provide a limited degree of discretion from commercial competitors searching public filings—nothing more.

Substance appearance for tax purposes

The second historical rationale was that a nominee director in Jurisdiction X would help demonstrate that a company was managed and controlled from Jurisdiction X, justifying tax residency there and access to Jurisdiction X's tax treaty network.

This has not held up to regulatory scrutiny. Tax authorities apply the Place of Effective Management (POEM) test to determine corporate tax residency in cases of dispute. POEM asks where the senior management decisions necessary for the conduct of the entity's business are actually made—not where the nominal directors are located.

A nominee director who rubber-stamps decisions made by a UBO in a different country does not move the POEM. The relevant question is where the beneficial owner actually exercises control. Courts and tax authorities in multiple jurisdictions have consistently disregarded nominee arrangements when assessing POEM, finding that a director who acts purely on instruction without independent judgment does not constitute genuine management presence.

Under BEPS Action 6 (preventing the granting of treaty benefits in inappropriate circumstances), the OECD introduced the Principal Purpose Test (PPT), now incorporated into more than 2,000 tax treaties through the Multilateral Instrument (MLI). The PPT denies treaty benefits where one of the principal purposes of an arrangement is to obtain those benefits—regardless of whether the formal structure is technically compliant. A nominee director arrangement used specifically to access treaty benefits that the UBO could not otherwise claim is precisely the type of arrangement the PPT targets.

The practical result: nominee directors do not create substance where none exists. In fact, a nominee who does not genuinely exercise independent management judgment can worsen a company's POEM position—because it removes even the argument that the formal director contributes real management activity.

When nominee directors are legitimate

With the privacy and substance rationales substantially weakened, the remaining legitimate use cases are specific and narrow.

Meeting local director residency requirements

Some jurisdictions require that at least one director be ordinarily resident in that jurisdiction. This is a statutory compliance requirement, not a tax strategy. Examples:

• Singapore: Section 145 of the Companies Act requires every private limited company to have at least one director ordinarily resident in Singapore at all times. If no founder qualifies, a locally licensed nominee director is required to incorporate.
• Canada (federal): Under the Canada Business Corporations Act, at least 25% of directors of federally incorporated companies must be resident Canadians, though this requirement is under ongoing review.
• Ireland and other EU jurisdictions: While the EU single market permits companies to appoint directors from any EU member state, some jurisdictions have practical or statutory preferences for local directors linked to banking and regulatory filings.
• Japan: Foreign companies incorporating in Japan must have a Japanese-resident representative director.

In these cases, a nominee director serves a genuine statutory compliance function. The key characteristic distinguishing legitimate use: the residency requirement is imposed by law and the nominee is provided by a licensed corporate service provider, not assembled privately to manufacture a tax position.

Even in these cases, the nominee does not substitute for understanding your actual tax residency. A Singapore company with a locally compliant nominee director is still a Singapore company — but if its beneficial owner makes all strategic decisions from Germany, German tax authorities may assert that the company's POEM is in Germany.

Situations where the nominee exercises genuine independent judgment

A nominee director who actually participates in governance — attending board meetings, reviewing financial statements, exercising professional judgment about fiduciary duties — is performing a different function from a pure rubber-stamp arrangement. Independent non-executive directors in regulated industries are a related concept: they add genuine oversight and carry professional liability for their decisions.

Where a nominee director genuinely contributes management participation and carries professional liability for their role, the arrangement has more legal substance. This is qualitatively different from a nominee whose only function is to hold a title.

When nominee directors create problems

The rubber-stamp POEM problem

A nominee who signs documents on instruction without independent judgment does not fix a POEM issue — it can create one. Tax authorities examining corporate residency will ask: what did this director actually decide? If the answer is "nothing — they acted entirely on the beneficial owner's instructions," that answer actively undermines the claim that the company is managed from the nominee's jurisdiction.

For founders operating from a country that taxes on worldwide corporate income, or from a country with controlled foreign corporation (CFC) rules, a nominal nominee director in an offshore structure does not remove the risk that their home country will assert tax residency over the company.

Treaty access and BEPS Action 6

Nominee director structures designed specifically to access treaty benefits — for example, routing income through a holding company in a treaty-favorable jurisdiction using a nominee director to establish nominal "residence" — are now directly targeted by the PPT in the MLI. The test is whether a principal purpose of the arrangement was to obtain the treaty benefit. The answer, where a nominee was used specifically to establish treaty-country presence, is likely yes. Treaty benefits can be denied entirely.

Banking and financial institution scrutiny

Banks globally now treat nominee arrangements as an AML risk signal requiring Enhanced Due Diligence. Where a company has nominee directors, banks typically require disclosure of the full beneficial ownership chain, source-of-funds documentation, and ongoing monitoring. This does not disqualify a company from banking — but it adds friction, delays account opening, and increases ongoing compliance costs. For smaller companies, the practical banking difficulty can outweigh whatever benefit the nominee arrangement provides.

The liability question

Nominee directors carry legal liability for the companies they direct. A nominee who discovers the beneficial owner is using the company for activities that create legal risk — including tax fraud, money laundering, or other misconduct — has personal exposure as a named director. Reputable licensed corporate service providers price this risk into their fees and maintain professional indemnity insurance. Informal nominee arrangements with individuals who don't understand their exposure create risk for both the nominee and the UBO.

Legitimate versus problematic: a comparison

What nominee director services actually cost

Typical nominee director fees range from €500 to €2,000 per year for standard arrangements in offshore jurisdictions, rising to €3,500–€6,500 in regulated financial centers like Singapore. UK nominee director services typically run GBP 1,500–GBP 2,500 per year.

These fees are almost always bundled with related services: a registered office address, a company secretary function, and annual filing services. The bundle is often presented as cost-effective because no single element is expensive in isolation. The relevant question is whether any element of the bundle actually serves a genuine function for your structure.

A typical bundled package for an offshore company with a nominee director and registered office might cost €800–€2,500 per year total, covering:

• Nominee director annual fee
• Registered office address
• Annual compliance and filing fees
• Company secretarial services

For a small founder with a genuinely simple structure, this is a recurring cost that buys limited benefit in 2026's transparent regulatory environment. For a company with a specific statutory need for a local director, it is a necessary compliance cost.

The substance question nominee directors cannot answer

The issue nominee directors have historically been sold as solving — substance — is actually a different problem requiring a different solution.

Genuine substance in a jurisdiction means real economic activity: employees on payroll, office space with actual use, management decisions made by people physically present, contracts and banking relationships that reflect genuine local operations. This is what tax authorities look for when assessing whether a company is genuinely resident in a jurisdiction and whether its profits legitimately arise there.

For founders exploring how to structure a holding company effectively, substance is the core variable. A holding company structure can be legitimate and efficient — but its efficiency depends on meeting substance requirements in the chosen jurisdiction, not on who the nominal director is. Our guide to jurisdiction selection covers what substance requirements actually look like in practice across commonly used jurisdictions.

If you are exploring substance-based structures seriously, the starting point is understanding what substance requirements actually demand in your target jurisdiction — then assessing whether your business operations can genuinely meet them. Nominee directors are not part of that answer.

Honest assessment: does a nominee director make sense for you in 2026?

For most small founders and remote professionals building international structures, the answer is no — at least not for the reasons nominee services are typically marketed.

The privacy benefit is substantially gone. UBO registers, CRS reporting, and bank KYC requirements mean your identity as the beneficial owner is disclosed to authorities regardless of who appears as director in public filings. The commercial privacy benefit (competitors can't easily see your name in public records) remains marginal and is probably not worth the cost and compliance friction.

The substance benefit was always illusory. A nominee director never created genuine substance and now actively signals risk to banks and regulators in ways that can complicate operations.

The treaty benefit angle is now directly targeted by BEPS Action 6's PPT in over 2,000 tax treaties. Structures designed around this rationale carry significant exposure.

What remains are specific, bounded situations:

• Your target jurisdiction legally requires a locally resident director and you don't qualify
• You need a professionally licensed corporate service provider who can serve a genuine governance function, not just hold a title

If you find yourself in one of those situations, the right approach is to use a licensed provider in the relevant jurisdiction, document the arrangement properly, and understand clearly that the nominee's presence does not substitute for actual substance — including understanding your own tax residency position as the beneficial owner.

If you're uncertain whether your structure genuinely needs a nominee director or whether your real objective is better served by a different approach, that's a conversation worth having with a qualified corporate and tax advisor before committing to an arrangement with ongoing costs and compliance implications.

Key points

• A nominee director appears in public company records but acts on behalf of the beneficial owner; the UBO retains actual authority and economic interest
• The privacy rationale for nominee directors has been substantially eliminated by UBO registers, the UK PSC register, CRS reporting, and bank KYC requirements — your identity as beneficial owner is known to tax authorities regardless
• Nominee directors do not create substance or fix a POEM problem; a pure rubber-stamp nominee can worsen a company's tax residency position by removing even the argument that the nominal director contributes genuine management
• BEPS Action 6's Principal Purpose Test, embedded in 2,000+ tax treaties through the MLI, directly targets structures where nominees are used to claim treaty benefits the beneficial owner couldn't access directly
• Legitimate remaining uses: meeting statutory local director residency requirements (Singapore, Canada, Japan, others); genuine professional governance participation by a licensed director with fiduciary liability
• Cost: €500–€2,000/year in most offshore jurisdictions; SGD 3,500–SGD 6,500 in Singapore; often bundled with registered office and secretarial services
• For most small founders in 2026, a nominee director adds cost and compliance friction without meaningful benefit; the scenarios where one genuinely helps are narrow and specific

The information in this guide is for research and educational purposes. It does not constitute legal or tax advice. Corporate law, beneficial ownership regulations, and tax treaty rules change frequently — always verify current requirements with a licensed advisor in the relevant jurisdiction before making structural decisions.

The information in this article is for research and educational purposes only. It does not constitute legal or tax advice. Program rules, investment thresholds, and government fees change frequently — always verify current requirements with a licensed advisor before taking action.